
|Videos|February 23, 2018
Long-Term Follow-Up Results From the ZUMA-1 Trial in Non-Hodgkin Lymphoma
Author(s)Sattva S. Neelapu, MD
Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses long-term findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory aggressive non-Hodgkin lymphoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Varegacestat Achieves PFS Gains, Deep Shrinkage of Desmoid Tumors
3
Deep Proteomic, AI Breast Cancer Detection Test Demonstrates High Performance
4
Erdafitinib Demonstrates Manageable Toxicity, Early Efficacy in Glioma
5









































